These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Lyon M; Moore DH Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806 [TBL] [Abstract][Full Text] [Related]
24. Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial. Mitsumoto H; Cheung K; Oskarsson B; Andrews HF; Jang GE; Andrews JA; Shah JS; Fernandes JA; McElhiney M; Santella RM Trials; 2023 Jul; 24(1):449. PubMed ID: 37430314 [TBL] [Abstract][Full Text] [Related]
25. Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial. Al-Chalabi A; Shaw P; Leigh PN; van den Berg L; Hardiman O; Ludolph A; Aho VV; Sarapohja T; Kuoppamäki M J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1165-1170. PubMed ID: 31315908 [TBL] [Abstract][Full Text] [Related]
26. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Gordon PH; Moore DH; Miller RG; Florence JM; Verheijde JL; Doorish C; Hilton JF; Spitalny GM; MacArthur RB; Mitsumoto H; Neville HE; Boylan K; Mozaffar T; Belsh JM; Ravits J; Bedlack RS; Graves MC; McCluskey LF; Barohn RJ; Tandan R; Lancet Neurol; 2007 Dec; 6(12):1045-53. PubMed ID: 17980667 [TBL] [Abstract][Full Text] [Related]
28. Granulocyte-colony stimulating factor administration for neurological improvement in patients with postrehabilitation chronic incomplete traumatic spinal cord injuries: a double-blind randomized controlled clinical trial. Derakhshanrad N; Saberi H; Yekaninejad MS; Joghataei MT; Sheikhrezaei A J Neurosurg Spine; 2018 Jul; 29(1):97-107. PubMed ID: 29701561 [TBL] [Abstract][Full Text] [Related]
29. Effects of continuous high-dose G-CSF administration on hematopoietic stem cell mobilization and telomere length in patients with amyotrophic lateral sclerosis - a pilot study. Iberl S; Meyer AL; Müller G; Peters S; Johannesen S; Kobor I; Beier F; Brümmendorf TH; Hart C; Schelker R; Herr W; Bogdahn U; Grassinger J Cytokine; 2019 Aug; 120():192-201. PubMed ID: 31100684 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of mecasin for treatment of amyotrophic lateral sclerosis: A phase IIa multicenter randomized double-blinded placebo-controlled trial. Kim S; Yang M; Ku B; Cha E; Seo W; Son I; Kang H; Kim D; Song B; Yang CS; Kim S J Ethnopharmacol; 2023 Oct; 315():116670. PubMed ID: 37257710 [TBL] [Abstract][Full Text] [Related]
31. Granulocyte Colony-Stimulating Factor Ameliorates Skeletal Muscle Dysfunction in Amyotrophic Lateral Sclerosis Mice and Improves Proliferation of SOD1-G93A Myoblasts in vitro. Rando A; Gasco S; de la Torre M; García-Redondo A; Zaragoza P; Toivonen JM; Osta R Neurodegener Dis; 2017; 17(1):1-13. PubMed ID: 27544379 [TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B; Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198 [TBL] [Abstract][Full Text] [Related]
33. Study protocol for Near-infrared molecular imaging for lung cancer detection and treatment during mini-invasive surgery (phase II Trial) - (the RECOGNISE study). Beffa ED; Lyberis P; Rosboch GL; Arezzo A; Lococo F; Carena L; Sciorsci E; Monica V; Lausi PO; Dusi V; Busardò FP; Buffa E; Stefania R; Ciccone G; Monagheddu C; Capello BM; Vancheri R; Garrone P; Gabbarini F; Cattel F; Ruffini E; Guerrera F BMC Cancer; 2024 Sep; 24(1):1078. PubMed ID: 39218855 [TBL] [Abstract][Full Text] [Related]
34. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. Snowden JA; Biggs JC; Milliken ST; Fuller A; Staniforth D; Passuello F; Renwick J; Brooks PM Bone Marrow Transplant; 1998 Dec; 22(11):1035-41. PubMed ID: 9877264 [TBL] [Abstract][Full Text] [Related]
35. Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. Park SB; Vucic S; Cheah BC; Lin CS; Kirby A; Mann KP; Zoing MC; Winhammar J; Kiernan MC EBioMedicine; 2015 Dec; 2(12):1916-22. PubMed ID: 26844270 [TBL] [Abstract][Full Text] [Related]
36. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial. Lombardo FL; Spila Alegiani S; Mayer F; Cipriani M; Lo Giudice M; Ludolph AC; McDermott CJ; Corcia P; Van Damme P; Van den Berg LH; Hardiman O; Nicolini G; Vanacore N; Dickie B; Albanese A; Puopolo M; Trials; 2023 Dec; 24(1):792. PubMed ID: 38053196 [TBL] [Abstract][Full Text] [Related]
37. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Martinez HR; Gonzalez-Garza MT; Moreno-Cuevas JE; Caro E; Gutierrez-Jimenez E; Segura JJ Cytotherapy; 2009; 11(1):26-34. PubMed ID: 19191058 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. de la Rubia JE; Drehmer E; Platero JL; Benlloch M; Caplliure-Llopis J; Villaron-Casales C; de Bernardo N; AlarcÓn J; Fuente C; Carrera S; Sancho D; GarcÍa-Pardo P; Pascual R; JuÁrez M; Cuerda-Ballester M; Forner A; Sancho-Castillo S; Barrios C; Obrador E; Marchio P; Salvador R; Holmes HE; Dellinger RW; Guarente L; Estrela JM Amyotroph Lateral Scler Frontotemporal Degener; 2019 Feb; 20(1-2):115-122. PubMed ID: 30668199 [TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A; Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349 [TBL] [Abstract][Full Text] [Related]
40. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]